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Abstract: Drug classes used in the treatment of Chronic Obstructive Pulmonary Disease (COPD) have
not changed for many years, and none to date have shown disease-modifying activity. Statins are
used to help reduce cardiovascular risk, which is high in many patients with COPD. Their use has
been associated with improvements in some respiratory manifestations of disease and reduction in
all-cause mortality, with greatest reductions seen in patients with the highest inflammatory burden.
The mechanism for these effects is poorly understood. Neutrophils are key effector cells in COPD,
and correlate with disease severity and inflammation. Recent in vitro studies have shown neutrophil
functions are dysregulated in COPD and this is thought to contribute both to the destruction of lung
parenchyma and to the poor responses seen in infective exacerbations. In this article, we will discuss
the potential utility of statins in COPD, with a particular emphasis on their immune-modulatory
effects as well as presenting new data regarding the effects of statins on neutrophil function in vitro.
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1. Introduction
COPD is a chronic inflammatory condition of the lungs associated with significant systemic
manifestations and co-morbidities [1]. It is defined by expiratory airflow obstruction that is not
fully reversible (by bronchodilation) and during the course of the disease nearly all patients decline
functionally, symptomatically and physiologically as well as demonstrating continued progressive lung
damage [2]. COPD is heterogeneous and encompasses a number of diseases and syndromes, termed
phenotypes due to their impact on clinical outcomes. Recognised phenotypes include emphysema,
bronchiolitis, bronchiectasis, chronic bronchitis, bacterial colonisation, and frequent exacerbations
(or flares in symptoms often requiring additional short-term treatment with corticosteroids and
antibiotics) and patients suffer with differing burdens of each of these disease manifestations.
Of all the co-morbidities associated with COPD, one of the most important is cardiovascular
disease (CVD). COPD patients have a higher risk of CVD than people without COPD [3,4], even when
shared major risk factors (including smoking, hypertension, diabetes, inactivity, poor diet, and older
age) are considered [5–7].
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COPD is now the third leading cause of death world-wide [8] and is a major cause of morbidity and
hospital admissions. In the UK, COPD is estimated to cost the economy £3billion per year, with NHS
costs of £900 million annually [9]. In the developed world, cigarette smoking is the most important
risk factor for disease and around 80% of COPD patients are current or ex-smokers [10] however there
is emerging impact of biomass fuel use on disease prevalence in less developed countries [11,12] and
despite the decline in smoking the burden of COPD continues to rise.
There are currently no disease modifying medications in COPD, and the mainstay of treatment
remains bronchodilators and generic anti-inflammatory corticosteroids, although there is controversy
about their high utility in this disease [13]. There is a pressing need for new treatments, but with the
increasing costs of drug discovery, there is renewed emphasis on the repurposing of drugs in different
clinical settings to gain maximal benefit from the therapies we already have.
1.1. Inflammation, the Neutrophil, and COPD
COPD is associated with an abnormal, chronic, and injurious inflammatory response [14].
A large body of research supports a central role of the neutrophil in these inflammatory processes.
Airway neutrophilia is a feature of COPD, shown in all clinical phenotypes including patients
with a predominance of emphysema, with chronic bronchitis and bacterial colonisation, frequent
exacerbators, and even those with evidence of higher eosinophil activity [15]. The degree of this
neutrophilia also correlates with severity of disease and rate of physiological decline [16,17]. Neutrophil
proteinases, especially neutrophil elastase, are implicated in all pathological features of COPD in vitro
and in animal models [15]; proteinases released by neutrophils are associated with the development
of emphysema [18], contribute to destruction of the extracellular matrix [19] and are associated with
mucus hypersecretion [20].
Neutrophils are the dominant circulating leukocyte and represent a key component of the innate
immune system. In response to infection/inflammation, neutrophils leave the circulation and migrate
to sites of infection where they utilise a variety of mechanisms to contain and kill invading pathogens.
This includes phagocytosis, degranulation, production of reactive oxygen species (ROS), and release of
neutrophil extracellular traps (NETs).
Neutrophils are recruited to areas of inflammation by responding to inflammatory mediators
released from inflamed or infected tissue, such as Interleukin 8 (CXCL8) and leukotriene B4 (LTB4).
Laminar blood flow through post capillary venules forces heavier leukocytes (including neutrophils)
against the endothelial walls. During inflammatory events, endothelial cells upregulate the expression
of selectins (P-selectin, E-selectin) and intercellular Adhesion Molecule (ICAM) adhesion molecules
on their luminal surfaces [21] which bind P-selectin glycoprotein ligand-1 (PSGL-1), L-selectin and
integrins such as CD11a/CD18 on the neutrophil, supporting neutrophil capture and transmigration
through endothelium into the tissues [22]. Before neutrophil movement can initiate, the cell
must orientate and polarise itself along the gradient formed by increasing inflammatory mediator
concentrations by a mechanism known as “compassing” and then form pseudopods that effectively
drag the cell in the required direction [23,24]. Pseudopod formation is stimulated by an intracellular
process controlled by the localisation of Phosphatidylinositide 3-kinase (PI3K), SH-2 containing
inositol 5’-polyphosphatase 1 (SHIP1), and Phosphatase and tensin homolog (PTEN). PI3K converts
Phosphatidylinositol 4,5-bisphosphate (PIP2) into Phosphatidylinositol (3,4,5)-triphosphate (PIP3)
which has downstream effectors that induce F-actin polymerisation and protrusion of actin filaments
from the neutrophil membrane; thus creating a pseudopod [25]. SHIP1 and PTEN regulate the reverse
reaction and reduce the amount of local PIP3, preventing actin polymerisation but also deactivating
integrins [26].
For a neutrophil to migrate in the correct direction, it must have higher PI3K activation in the area
of the cell facing the chemical gradient (leading edge) and higher SHIP1, PTEN activation (to impede
PI3K activity) on cell surfaces opposite to the leading edge (the uropod). This creates an anterior
posterior PIP3 gradient, polarising the neutrophil [27]. The activity of SHIP1, PTEN, and PI3K are
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regulated by small GTPases. GTPases are a large family of hydrolase enzymes that can bind and
hydrolyze guanosine triphosphate. They switch between inactive GDP bound forms and the active
GTP bound forms in order to trigger the activation of PI3K and PTEN in their correct cytosolic locations.
The activity of the small GTPases is initiated by the binding of chemoattractants such as LTB4 and
CXCL8 to the neutrophil surface [28].
Cigarette smoke (CS) contains a multitude of toxic products and is thought to initiate the
inflammatory processes within the lungs in COPD in most patients [29]. Initially, epithelial cell
damage by CS causes release of damage associated molecular patterns (DAMPs) which interact with
pathogen recognition receptors (PRRs) and toll-like receptors (TLRs) on other epithelial cells, resulting
in the release of inflammatory cytokines such as CXCL8. The resultant infiltration of inflammatory
cells—predominantly neutrophils, but also macrophages and T-cells—into the lung perpetuates
further cytokine release, resulting in this chronic inflammatory condition and the degree of the
inflammatory response correlates with lung disease severity [30]. As neutrophils migrate through
complex tissues, they release ROS and proteinases to facilitate their movement. Alpha-1 antitrypsin
(AAT) is an anti-proteinase and inhibits neutrophil elastase on a 1:1 basis, however the interstitial
concentration of AAT is significantly lower than that of neutrophil elastase following release from the
cell [31] leading to an area of uninhibited elastase activity with subsequent obligate tissue damage [32].
COPD is chronically associated with vast numbers of neutrophils passing through the lungs [33] and
so the capacity for tissue damage is considerable and sustained.
Once neutrophils reach their target sites, they have a number of methods to remove bacterial
colonies and cell debris in the lung; phagocytosis, degranulation and release of antimicrobial peptides,
respiratory burst (release of ROS), and NETosis (release of extracellular meshwork laden with
antimicrobial agents).
Phagocytosis is a receptor mediated process whereby the neutrophil binds bacteria through
IgG and complement opsonisation or Pathogen Associated Molecular Patterns (PAMPs) [34] before
engulfing and containing the bacteria within an internal phagosome. The phagosome fuses with
intracellular granules (forming a phagolysosome) and exposes the microbe to various anti-microbial
agents and proteins [35]. The respiratory burst is also stimulated by endocytosis of bacteria and results
in the exposure of engulfed microbes to toxic oxidative products. ROS production is catalysed by
NADPH oxidase which forms on the internal membrane of the phagosome and converts oxygen to toxic
hydrogen peroxide and hydroxide radicals [36]. Increased oxidative stress increases airway mucous
secretion in animal models through upregulation of the mucin gene, which stimulates differentiation
of epithelial cells to goblet cells [37–39]. Both ROS release and phagocytosis require small GTPase
activity within the cell, which coordinate the required cytoskeletal reorganisation needed to move
bacteria and ROS generating constituents into close proximity [40].
NETs are extracellular DNA meshworks laden with azurophillic and specific granule proteases
and histones which neutrophils release in some inflammatory environments. The NET effectively
captures microbes and provides a platform for bacteriocidal proteinases and histones [41]. NET release
is mediated by protein kinase C (PKC), which activates the GTPase Rac2 and forms part of the NADPH
oxidase complex. ROS production is increased in the cytosol and perforates the neutrophils own
nuclear envelope allowing the granule proteinases to mix with the nuclear DNA and histones to form
a NET chromatin lattice. Permeation of the neutrophil membrane then releases the NETs [42].
Initially, there was controversy as to whether the sustained neutrophilic inflammation present
in COPD was a ubiquitous response to the inflammatory environment caused by CS (or other toxic
environmental exposures), or whether neutrophil functions, and the resultant inflammation, were
dysregulated in COPD, and a fundamental component of disease. There is a building body of evidence
to support the latter hypothesis. Only a quarter of smokers develop clinically significant COPD [43] and
smoking cessation does not resolve neutrophilic inflammation in patients with COPD, in contrast with
smoking controls [44–46], supporting the presence of other—as yet undefined—susceptibility factors
for disease pathogenesis. Furthermore, previous work from our group has shown distinct alterations in
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the ability of neutrophils from patients with COPD to migrate towards a plethora of chemo-attractants;
whereby cells migrate with increased overall speed, but reduced migrational accuracy [47]. Hence,
despite being able to move faster, these neutrophils have a reduced ability to move directly towards
inflammation or invading bacteria. Recent studies also suggest that following pathogen clearance,
a proportion of neutrophils may return to the vasculature [48]. In these circumstances, the obligate
area of tissue damage [49] (described earlier) may be increased; due to the more circuitous routes
of migration both to and then from the inflamed tissues, both in the lung and systemic vasculature.
In keeping with this, endothelial dysfunction is a well-recognised feature of COPD [50] and is in part
mediated by neutrophil proteinases and reactive oxygen species [51]. As well as reduced migratory
accuracy, neutrophils from COPD have been associated with enhanced respiratory burst responses
(both spontaneous production and following stimulating with phorbol myristate acetate (PMA) [52,53])
and one study has implicated neutrophil NETs in COPD (with NET content in sputum correlating
with disease severity) [54]. Also, it has been speculated that infiltrating dendritic cells may collect and
present some of the high volumes of self-DNA released as NETs, potentially stimulate an autoimmune
response in COPD [55], where anti-elastase autoantibodies have been both described and pathologically
associated with disease [56]. NETs have also been associated with tissue damage and disease including
endothelial dysfunction and atherosclerosis [57,58]. Hence, the neutrophil is increasingly recognised as
an immunotherapeutic target in COPD [59] but it is unclear which treatments might positively impact
on cellular functions associated with tissue damage without impairing their crucial bactericidal activity.
1.2. Cholesterol, Statins, and Cardiovascular Disease
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) Reductase Inhibitors (commonly referred
to as “Statins”) are primarily indicated for the treatment of dyslipidaemia, to reduce cardiovascular risk.
The evidence supporting statin-associated CVD risk reduction is extremely robust (for example, [60])
and statins appear safe and well tolerated in many patients [61]. The primary mechanism of action is
inhibition of HMG-CoA reductase, an enzyme which catalyses the reaction between HMG-CoA and
mevalonate, and forms the rate-limiting step of cholesterol synthesis, thereby statins are able to reduce
cholesterol (see Figure 1).
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However, evidence has consistently shown that statins reduce all-cause mortality irrespective of
baseline low-density lipoprotein (LDL) cholesterol [62,63] with the proportional reduction in major
vascular events the same in both low and high risk patients [62]. This, and other research, has led to
the currently controversial hypothesis that cholesterol is not causally associated with cardiovascular
disease [64], and that the therapeutic effects of statins may reflect their other, pleiotropic mechanisms
of action, in particular those which are anti-inflammatory or immunomodulatory.
In addition to reducing cholesterol synthesis, statins also reduce production of all products
downstream of HMG-CoA, including inhibition of isoprenoid production. Isoprenoids are utilised
by cells for the post-translational modification and activation of small GTP-ases such as Ras and
Rho; molecules that are essential for a number of inflammatory cellular functions including adhesion,
cell recruitment, and immune cell de-granulation [65,66] (as outlined above). See Table 1 for a summary
of the pleiotropic immune-modulatory and anti-inflammatory actions of statins.
Table 1. The anti-inflammatory and immunomodulatory effects of statins.
Effect Model/Cell-Type Reference
Increased NF-IκB expression Human hepatocytes [67]
Human endothelial cells [68]
Phosphorylation of Akt Human endothelial cells [69]
Decreased TNFα production Human volunteers [70]
Decreased IL-6 production Human volunteers [70]
Mice [71]
Increased IL-12 production Mouse peritoneal macrophages [72]
Reduced plasma C-reactive protein Human volunteers [70]
Human hepatocytes [67]
Reduced expression of P-Selectin Rat mesenteric endothelium [73]
Reduced superoxide production Human monocytes [74]
Inhibition of matrix metalloproteinase production Human lung fibroblasts [75]
Regulation of Th1/Th2 polarisation Mice [76]
Block of LFA-1 ICAM interaction Various: isolated proteins, cell lines, murine model [77]
Inhibition of MHC expression Human macrophages & endothelial cells [78]
Inhibition of monocyte chemotactic protein-1 synthesis Human peripheral blood mononuclear cells [79]
There is evidence that inflammation is central to CVD with C-Reactive Protein (CRP) and
tumour necrosis factor alpha (TNFα) concentrations predictive of cardiovascular events [80,81].
There is also significant data to support mevalonate pathway activation in CVD. Endothelial
dysfunction/plaque formation in CVD is associated with increased adhesion molecule expression
via Rho activity and, across classes, statins have been shown to reduce adhesion molecule expression
in both immune and endothelial cells via inhibition of GTPases [82,83]. Atherosclerotic plaques are
characterised by immune cell infiltration and statins have been shown to reduce this both via the
reduction of plaque/endothelial derived chemoattractants and by altering immune cell function
to reduce pro-inflammatory activity [84]. Plaque formation has been associated with macrophage
and T cell infiltration, increased MMP-2 expression (a macrophage derived proteinase) and collagen
proteolysis, while statins reduce the cellular content of plaques, increase tissue inhibitor of MMP-1
(an anti-proteinase) and are associated with a higher collagen content, suggesting a stabilizing effect of
atherosclerotic lesions by reducing proteolysis [85].
Neutrophilic inflammation is a central component of atherosclerosis [86,87] and there is
an increasing interest in the neutrophil’s role in CVD. Neutrophil numbers are associated with impaired
microvascular perfusion, left ventricular dilation and adverse cardiac events in patients treated for
myocardial infarction [88]. Furthermore, myeloperoxidase (a marker of neutrophil activity) is increased
acutely following myocardial damage and predicts CVD outcomes [88,89]. Neutrophils promote clot
formation through interactions with platelets, proteolytic cleavage of clotting factors, and release
of prothrombotic NETs [90]. Neutrophils promote atherosclerosis and plaque rupture by enhancing
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monocyte and further neutrophil infiltration, producing oxidized low density lipoprotein (oxLDL),
and releasing proteolytic enzymes that degrade the fibrous cap of the plaque [91]. Statins are known
to impact on many of these inflammatory processes. Studies have described reduced adhesion of
neutrophils to fibronectin with 10 µm simvastatin and a decline in activated expression of CD11b [92]
and demonstrated that statins are able to reduce degranulation [93], migration [94], and netosis [95]
during inflammatory events.
Many of the inflammatory processes associated with CVD (and described above) have also been
described in the pathology of COPD, where pulmonary and systemic inflammation is also significantly
raised [33]. In light of this, it has been hypothesised that lung damage in COPD and cardiovascular
events may share a common inflammatory pathology, with the severity of one predicting the onset of
the other [96]. See Figure 2 for a schematic of how neutrophilic inflammation may be implicated both in
COPD and CVD. This has potential importance, as disease-modifying drugs that target inflammation
in COPD may reduce cardiovascular events, and treatments that reduce cardiovascular morbidity may
impact on COPD progression in this high-risk population. Since statins have been shown to modify
inflammatory processes implicated in both diseases, there are theoretical reasons to consider their use
in COPD, not just to modify cardiovascular risk but also to treat manifestations of lung disease.
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Figure 2. Shared inflam atory mechanisms in COPD and CVD. Chronic cigarette s o ex s r or
other toxic inhalants in su ceptible peopl leads to (1) the sustained activation of airway macrophages
and epithelial cells; (2) The rel a e of inflamm tory cytokines causes endothelial activation nd
neutroph ls recruitment to the airways, however COPD p or migratory accuracy and increased reactive
oxygen pecies release leads to (3) inc ased systemic inflammation. This activates endothelial cells
further, r cruiting more neutrophils and as well as causing (4) bystander tissue damage to both blood
vessels and the lung parenchyma; (5) Neutrophil proteinases degrade elastin fibres both in the lung
and large blood vessels, causing emphysema and arterial stiffness as well as increasing the activity of
macrophage proteinases such as MMP12. Neutrophil netosis (6) adds to the inflammatory burden, and
promotes platelet aggregation in small vessels due to endothelial damage (7). Atherosclerotic plaques
form over areas of endothelial damage, which are infiltrated by immune cells including neutrophils
during plaque rupture.
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1.3. Statins and Clinical Outcomes in COPD
There are an increasing number of studies examining the potential impact of statin use in
COPD. Observational studies of COPD have described a slower decline in pulmonary function
in patients taking statins [97,98]. Furthermore, a number of retrospective, observational studies
have reported statin-associated reductions in death from infection (pneumonia and influenza) [99],
all-cause mortality [100] and a recent meta-analysis of cohort studies detected a protective effect of
statin treatment on the risk of COPD exacerbation with or without hospitalization [101]. In animal
models, statins have been shown to be protective against the development of emphysema, inhibiting
lung parenchymal destruction and the development of pulmonary hypertension. In the same
study, statins also inhibited peribronchial and perivascular inflammatory cell infiltration in lung
tissue [102]. In human studies, statins have been shown to reduce endothelial dysfunction and
systemic inflammation [103].
However, these results have not been universally replicated and some studies have shown
no benefit [104] including a recent meta-analysis of randomised controlled trials in COPD [105].
The discordance between observational studies, in vitro studies, animal models (which generally show
benefit), and interventional trials (which often do not) mirrors the situation seen for research into statin
use in sepsis [106] and the reason for the disparity may reflect experimental design. Observational
studies usually include older patients who have been taking statins for many months, in vitro cellular
studies often utilise high concentrations of statins (which sometimes exceed standard prescribing
regimes by over 10-fold), while clinical trials have often used low dose statins in patients of varying
age as an acute intervention. Furthermore, clinical trials have utilised statins for short periods of
time. Some patients experience side effects with statin use including (albeit rarely) potentially serious
adverse events such as rhabdomyolysis and hepatitis, and these must be carefully considered when
instigating a potentially long term treatment. Statins may be helpful adjuvants to treat inflammation in
COPD, but the questions are: which statin and at what dose? Which patients? When should treatment
start and for how long for?
All statins studied have shown some anti-inflammatory outputs in keeping with their shared
mechanism of action and therefore the choice of statin does not appear important in studies reported to
date. Current evidence points to a high dose being associated with improved inflammatory outcomes.
Simvastatin (5–20 mg/kg) used with inhalation injury in mice was effective in attenuating lung damage
but only at the higher dose [107]. In a double-blind placebo-controlled study, intravenous endotoxin
produced a detectable systemic inflammatory response which was prevented by pre-emptive dosing
with 80 mg Simvastatin in humans [108] but not at a lower dose.
The patient group under study is also likely to be important. The recently reported STATCOPE
study randomised COPD patients to receive 40 mg Simvastatin to determine impact on exacerbation
rates. Inclusion criteria included a diagnosis of COPD and the use of supplemental oxygen, receipt of
systemic glucocorticoids or antibiotic agents for respiratory problems, or presentation to the emergency
department or hospitalization for COPD exacerbation in the preceding year [109] but frequently
exacerbating patients (defined as two or more per year) were not specifically selected. This (and the
lower dose of 40 mg simvastatin) may have potentially impacted on findings.
Finally, the endpoint is likely to be crucial. It is unlikely that statins will act as a panacea
for all manifestations of COPD or all inflammatory processes. Dysregulated neutrophil functions
have been associated with tissue damage in COPD, particularly functions associated with increased
or indiscriminate neutrophil elastase activity, which in turn has been associated with emphysema.
If neutrophils are central to the development of COPD, one would expect a disease-modifying drug to
impact positively on these functions, and there is evidence to support this. In a small controlled trial,
statin therapy was associated with a decrease in sputum leptin, absolute neutrophil counts, and the
incidence of COPD exacerbations [110].
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2. Statins and Neutrophil Migration in COPD; In Vitro Studies
Previously, we identified increased migratory speed of movement in any direction (termed
chemokinesis) but reduced migratory accuracy towards inflammation (termed chemotaxis) in systemic
neutrophils isolated from patients with COPD and related this to systemic neutrophil elastase
activity and the potential for tissue damage [47]. We have studied the effects of therapeutically
relevant concentrations of Simvastatin on neutrophil migratory dynamics in both patients with
COPD (average age 69.5 years ± 8.5) and age-matched healthy control subjects (average age
64.4 years ± 12). Chemotaxis was assessed in neutrophils isolated from whole blood using an Insall
Chamber (Weber Scientific International Ltd., Teddington, UK) and time-lapse video microscopy,
as described previously [111]. Neutrophils were migrated towards 100 nm CXCL8 (R & D Systems,
Abingdon, UK) or 10 nm fMLP (Sigma-aldrich, Dorset, UK) for 12 min, parameters which were
optimised in a series of validation experiments. Cell migration was imaged using a Leica DM6000 B
microscope fitted with a DFC 360FX monochrome digital camera and migratory paths tracked using
the Java software, ImageJ (Wayne Rasband, NIH, Bethesda, MD, USA).
Neutrophils were incubated with Simvastatin sodium salt (Merck Millipore, Nottingham, UK)
at 1 nm or 1 µm or vehicle control (dimethyl sulfoxide) or buffer (negative control) for 40 min prior
to migration studies and statin concentrations were chosen to represent known steady-state plasma
concentrations of Simvastatin from 10 mg to 80 mg [112]. Appropriate incubation time was chosen
following appropriate time-course experiments. Of note, the same defect (increased chemokinesis
but reduced chemotaxis) was seen in COPD neutrophils compared to those from healthy controls
in untreated neutrophils, as previously described. Forty minutes of in vitro treatment of isolated
peripheral blood neutrophils with either 1 nm or 1 µm simvastatin was able to improve neutrophil
velocity towards both CXCL8 and fMLP in patients with COPD, restoring migratory accuracy to levels
seen in age-matched healthy control neutrophils. See Figure 3.
These results are in keeping with other in vitro assessments of the ability of statins to impact
upon pro-inflammatory events. Importantly in the studies described above, simvastatin did not
inhibit the ability of the cell to respond to infection/inflammation but rather improved it, however
there have not been studies of statin use and NETosis, phagocytosis, or ROS release in neutrophils
from COPD patients, and these would be needed to further assess the likely impact of statins on
crucial neutrophil functions. Evidence from other in vitro human studies have described potential
impairment of neutrophil bactericidal functions, but these have used non-therapeutic concentrations
(such as 10–50 µm rather than the therapeutic 1 µm [113]) making interpretation difficult. In contrast,
mouse studies utilising more relevant doses of drug have described reductions in NET formation in
murine models with improved responses to inflammatory challenges [95]. In summary, these early
studies by ourselves and others have suggested statins may impact positively on some neutrophil
functions thought central to the pathogenesis of both COPD and CVD, but further investigation
is required.
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Figure  3. Neutrophil migratory  accuracy  is  improved  in  COPD  following  in  vitro  exposure  to 
simvastatin.  Neutrophil  migratory  chemotaxis  (A,B)  (accuracy  of  movement  towards  a 
chemoattractant) and chemokinesis (C,D) (random speed of movement in any direction) from n = 8 
patients with COPD and n = 10 age‐matched healthy controls towards 100 nm CXCL8 (A,C) or 10 nm 
fMLP  (B,D) were  compared. White bars  represent healthy  controls  (HC) and gray bars  represent 
patients with COPD. “NC” is migration towards CXCL8 or fMLP when neutrophils were incubated 
with buffer alone, “VC” is migration towards the chemoattractants when neutrophils were incubated 




accurate when migrating  towards  fMLP and CXCL8. Simvastatin  improved accuracy of migration 
(chemotaxis)  towards  CXCL8  and  fMLP  in  patients  with  COPD,  and  towards  healthy  controls 
towards CXCL8. Simvastatin did not affect the speed of migration in either group. 
3. Conclusions 
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randomised  controlled  trials  have  shown  limited  efficacy  on  COPD‐related  outcomes  such  as 
exacerbation frequency. Disparity in COPD‐related results may reflect experimental design and the 














Figure 3. Neutrophil migratory accuracy is improved in COPD following in vitro exposure
to simvast tin. Neutrophil migratory chemotaxis (A,B) (accuracy of movement towards
a chemoattractant) and chemokinesis (C,D) (random speed of movement in any direction) fro n = 8
patients with COPD and n = 10 age-matched healthy controls towards 100 m CXCL8 (A,C) or 10 nm
fMLP (B,D) ere compared. White bars represent healthy controls (HC) and gray bars represent
patients with COPD. “NC” is migration towards CXCL8 or fMLP when neutrophils were incubated
with buffer alone, “VC” is migration towards the chemoattractants when neutrophils were incubated
in vehicle control. “Sim” is migration towards the chemoattractants when neutrophils were incubated
with simvastatin (concentrations as shown). Data presented as mean and standard error of the mean.
* represents p value < 0.05. Data was compared using Mann-Whitney-U or Kruskal Wallis tests.
Neutrophils from patients with COPD were faster than those from healthy controls, but less accurate
when migrating towards fMLP an CXCL8. Simvastatin improved accuracy of migration (chemotaxis)
towards CXCL8 and fMLP in patients with COPD, and towards healthy controls towards CXCL8.
Simvastatin did not affect the speed of migration in either group.
3. Conclusions
COPD remains a significant cause of mortality and morbidity globally, and our therapeutic tools
for reducing its impact are limited. There is clear evidence of improved CVD morbidity and mortality
in COPD following statin use, but the shared inflammatory mechanisms that have been described in
both COPD an CVD provide theoretical reasons to support the use of statins in COPD progression as
well. Statins have been associated with improved lung outcom s in in vitro xperime ts, in animal
models, a d i observational studie of COPD. However, results of andomised controlled trials
have shown limited efficacy on COPD-related outcomes such as exacerbation frequency. Disparity
in COPD-related results may reflect experimental design and the patients and outcomes that were
selected. The persistent signal reported in many studies has maintained interest in these drugs for this
debilitating disease. Further in vitro studies and proof of principle clinical trials using statins at high
doses—with cellular as well as cli ical outcom —in carefully selected pat ents may provide more
insight into their otential utility.
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